UTI Multi Cap Fund
The scheme seeks to generate long-term capital appreciation by investing predominantly in equity and equity related securities of companies across the market capitalization spectrum.
Growthvine rating: 2/5 — ranked #20 of 34 in category.
Fund basics
| Category | Equity: Multi Cap |
|---|
| NAV | ₹10.68 (as of 2026-11-13) |
|---|
| AUM | ₹2,113 Cr |
|---|
| Expense ratio | 1.75% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Karthikraj Lakshmanan |
|---|
| Exit load | 1% for redemption within 90 days |
|---|
Performance & risk
| Standard deviation | 0.00% |
|---|
| Max drawdown | −14.33% |
|---|
| Alpha | 0 |
|---|
| Beta | 0 |
|---|
Over 5 years, captured 89.7% of NIFTY500 Multicap 50:25:25's upside and 86.5% of its downside.
Market cap allocation
| Large cap | 43.3% |
|---|
| Mid cap | 28.2% |
|---|
| Small cap | 28.5% |
|---|
Concentration
| Top 5 holdings | 19.7% |
|---|
| Top 10 holdings | 30.7% |
|---|
| Total holdings | 69 |
|---|
| Index overlap | 27.4% |
|---|
| Active share | 72.6% |
|---|
Top holdings
- ICICI Bank Ltd. — 5.4%
- Kotak Mahindra Bank Ltd. — 4.9%
- HDFC Bank Ltd. — 4.7%
- NET CURRENT ASSETS — 4.5%
- AXIS Bank Ltd. — 2.4%
- Shriram Finance Limited — 2.3%
- COFORGE LIMITED — 2.3%
- VOLTAMP TRANSFORMERS LIMITED — 2.3%
- Oil India Limited — 2.2%
- Bharti Airtel Ltd. — 2.2%
Top sectors
- Banking & Financial — 19.8%
- Pharma & Biotech — 6.7%
- Automobile — 5.9%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 0.3% | Q4 (Bottom) | #31 of 33 |